Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
Add more filters










Publication year range
1.
Eur J Clin Invest ; 48 Suppl 2: e12951, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29757466

ABSTRACT

Neutrophils are key cells of innate immunity and during inflammation. Upon activation, they produce large amounts of superoxide anion (O2 -. ) and ensuing reactive oxygen species (ROS) to kill phagocytized microbes. The enzyme responsible for O2 -. production is called the phagocyte NADPH oxidase. This is a multicomponent enzyme system that becomes active after assembly of four cytosolic proteins (p47phox , p67phox , p40phox and Rac2) with the transmembrane proteins (p22phox and gp91phox , which form the cytochrome b558 ). gp91phox represents the catalytic subunit of the NADPH oxidase and is also called NOX2. NADPH oxidase-derived ROS are essential for microbial killing and innate immunity; however, excessive ROS production induces tissue injury and prolonged inflammatory reactions that contribute to inflammatory diseases. Thus, NADPH oxidase activation must be tightly regulated in time and space to limit ROS production. NADPH oxidase activation is regulated by several processes such as phosphorylation of its components, exchange of GDP/GTP on Rac2 and binding of p47phox and p40phox to phospholipids. This review aims to provide new insights into the role of the phosphorylation of the NADPH oxidase components, that is gp91phox , p22phox , p47phox , p67phox and p40phox , in the activation of this enzyme.


Subject(s)
NADPH Oxidases/metabolism , Neutrophils/enzymology , Bacterial Proteins/pharmacokinetics , Enzyme Activation/physiology , Enzyme Activators/pharmacology , Humans , NADPH Oxidase 2/metabolism , Phosphoproteins/metabolism , Phosphorylation/physiology , Tetradecanoylphorbol Acetate/pharmacokinetics
2.
Mol Biol Cell ; 26(20): 3606-14, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26310443

ABSTRACT

Immunosuppressive therapies using calcineurin inhibitors, such as cyclosporine A, are associated with a higher incidence of squamous cell carcinoma formation in mice and humans. Calcineurin is believed to suppress tumorigenesis in part through Nfatc1, a transcription factor expressed primarily in hair follicle bulge stem cells in mice. However, mice overexpressing a constitutively active Nfatc1 isoform in the skin epithelium developed increased spontaneous skin squamous cell carcinomas. Because follicular stem cells can contribute to skin tumorigenesis, whether the endogenous expression of Nfatc1 inhibits or enhances skin tumorigenesis is unclear. Here we show that loss of the endogenous expression of Nfatc1 suppresses the rate of DMBA/TPA-induced skin tumorigenesis. Inducible deletion of Nfatc1 in follicular stem cells before tumor initiation significantly reduces the rate of tumorigenesis and the contribution of follicular stem cells to skin tumors. We find that skin tumors from mice lacking Nfatc1 display reduced Hras codon 61 mutations. Furthermore, Nfatc1 enhances the expression of genes involved in DMBA metabolism and increases DMBA-induced DNA damage in keratinocytes. Together these data implicate Nfatc1 in the regulation of skin stem cell-initiated tumorigenesis via the regulation of DMBA metabolism.


Subject(s)
Carcinogenesis/chemically induced , Carcinogenesis/metabolism , NFATC Transcription Factors/deficiency , Skin Neoplasms/chemically induced , Skin Neoplasms/metabolism , Skin/drug effects , 9,10-Dimethyl-1,2-benzanthracene/isolation & purification , 9,10-Dimethyl-1,2-benzanthracene/pharmacokinetics , Animals , Carcinogens , Cytochrome P-450 CYP2E1/metabolism , DNA Damage , Hair Follicle/metabolism , Keratinocytes/metabolism , Mice , Mice, Knockout , NFATC Transcription Factors/biosynthesis , NFATC Transcription Factors/genetics , NFATC Transcription Factors/metabolism , Papilloma/chemically induced , Papilloma/genetics , Papilloma/metabolism , Skin/metabolism , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Stem Cells/metabolism , Tetradecanoylphorbol Acetate/pharmacokinetics , Tetradecanoylphorbol Acetate/toxicity
3.
Chin J Nat Med ; 13(1): 30-40, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25660286

ABSTRACT

The present study was designed to target fish for potential bioactive components contained in a Huang Lian Jie Du decoction (HLJDD) and identify the underlying mechanisms of action for the treatment of sepsis at the molecular level. he bioactive components database of HLJDD was constructed and the sepsis-associated targets were comprehensively investigated. The 3D structures of the PAFR and TXA2R proteins were established using the homology modelling (HM) method, and the molecular effects for sepsis treatment were analysed by comparing the bioactive components database and the sepsis targets using computational biology methods. The results of the screening were validated with biological testing against the human oral epidermal carcinoma cell line KB in vitro. We found that multiple bioactive compounds contained in the HLJDD interacted with multiple targets. We also predicted the promising compound leads for sepsis treatment, and the first 28 compounds were characterized. Several compounds, such as berberine, berberrubine and epiberberine, dose-dependently inhibited PGE2 production in human KB cells, and the effects were similar in the presence or absence of TPA. This study demonstrates a novel approach to identifying natural chemical compounds as new leads for the treatment of sepsis.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Berberine/pharmacokinetics , Drugs, Chinese Herbal/pharmacokinetics , Sepsis/drug therapy , Berberine/analogs & derivatives , Dinoprostone/biosynthesis , Drugs, Chinese Herbal/chemistry , Humans , KB Cells , Platelet Membrane Glycoproteins/drug effects , Protein Transport , Receptors, G-Protein-Coupled/drug effects , Receptors, Thromboxane A2, Prostaglandin H2/drug effects , Sepsis/metabolism , Tetradecanoylphorbol Acetate/pharmacokinetics
4.
Exp Biol Med (Maywood) ; 239(1): 83-93, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24131540

ABSTRACT

The antiallergic effects of traditional medicines have long been studied. Traditional Korean medicine, Citrus sunki and bamboo salt, has been used for the treatment of allergic diseases in Korea. K-ALL, composed of Citrus sunki and bamboo salt, is a newly prepared prescription for allergic patients. To develop the new antiallergic agent, we examined the effects of K-ALL through in vivo and in vitro models. K-ALL and naringin (an active compound of K-ALL) significantly inhibited histamine release from rat peritoneal mast cells. This inhibitory effect of K-ALL on histamine release was higher than effects from other known histamine inhibitors such as bamboo salt, Citrus sunki or disodium cromoglycate. K-ALL significantly inhibited systemic anaphylactic shock induced by the compound 48/80 and passive cutaneous anaphylaxis induced by the IgE. K-ALL also inhibited production and mRNA expression of inflammatory cytokines induced by phorbol 12-myristate 13-acetate and the calcium ionophore A23187 on HMC-1 cells (a human mast cell line). In the ovalbumin-induced allergic rhinitis animal model, rub scores, histamine, IgE, inflammatory cytokines and inflammatory cell counts were all reduced by the oral or nasal administration of K-ALL (pre and posttreatment). These results indicate the great potential of K-ALL as an active immune modulator for the treatment of mast cell-mediated allergic diseases.


Subject(s)
Anaphylaxis/drug therapy , Citrus/chemistry , Mast Cells/metabolism , Medicine, Korean Traditional , Plant Extracts/pharmacology , Rhinitis, Allergic, Perennial/drug therapy , Administration, Intranasal , Administration, Oral , Anaphylaxis/metabolism , Anaphylaxis/pathology , Animals , Calcimycin/pharmacology , Calcium Ionophores/pharmacology , Carcinogens/pharmacology , Cell Line , Cytokines/biosynthesis , Disease Models, Animal , Gene Expression Regulation/drug effects , Humans , Inflammation Mediators/metabolism , Male , Mast Cells/pathology , Mice , Mice, Inbred ICR , Plant Extracts/chemistry , Rats , Rats, Sprague-Dawley , Rhinitis, Allergic , Rhinitis, Allergic, Perennial/metabolism , Rhinitis, Allergic, Perennial/pathology , Tetradecanoylphorbol Acetate/pharmacokinetics
5.
Dig Dis Sci ; 57(5): 1203-12, 2012 May.
Article in English | MEDLINE | ID: mdl-22116644

ABSTRACT

AIM: In this study, we transfected the full length cDNA of glucose transporter 2 (GLUT2) into IEC-6 cells (which lack GLUT2 expression) to investigate GLUT2 translocation in enterocytes. The purpose of this study was to investigate cellular mechanisms of GLUT2 translocation and its signaling pathway. METHODS: Rat GLUT2 cDNA was transfected into IEC-6 cells. Glucose uptake was measured by incubating cell monolayers with glucose (0.5-50 mM), containing (14)C-D-glucose and (3)H-L-glucose, to measure stereospecific, carrier-mediated and passive uptake. We imaged GLUT2 immunoreactivity by confocal fluorescence microscopy. We evaluated the GLUT2 inhibitor (1 mM phloretin), SGLT1 inhibitor (0.5 mM phlorizin), disrupting microtubular integrity (2 µM nocodazole and 0.5 µM cytochalasin B), protein kinase C (PKC) inhibitors (50 nM calphostin C and 10 µM chelerythrine), and PKC activator (50 nM phorbol 12-myristate 13-acetate: PMA). RESULTS: In GLUT2-IEC cells, the K(m) (54.5 mM) increased compared with non-transfected IEC-6 cells (7.8 mM); phloretin (GLUT2 inhibitor) inhibited glucose uptake to that of non-transfected IEC-6 cells (P < 0.05). Nocodazole and cytochalasin B (microtubule disrupters) inhibited uptake by 43-58% only at glucose concentrations ≥25 and 50 mM and the 10-min incubations. Calphostin C (PKC inhibitor) reproduced the inhibition of nocodazole; PMA (a PKC activator) enhanced glucose uptake by 69%. Exposure to glucose increased the GFP signal at the apical membrane of GLUT-1EC cells. CONCLUSION: IEC-6 cells lacking GLUT2 translocate GLUT2 apically when transfected to express GLUT2. Translocation of GLUT2 occurs through glucose stimulation via a PKC-dependent signaling pathway and requires integrity of the microtubular skeletal structure.


Subject(s)
Cell Membrane , Enterocytes/metabolism , Glucose Transporter Type 2 , Glucose , Transfection/methods , Animals , Biological Transport , Cell Membrane/genetics , Cell Membrane/metabolism , DNA, Complementary , Glucose/metabolism , Glucose/pharmacokinetics , Glucose Transporter Type 2/antagonists & inhibitors , Glucose Transporter Type 2/genetics , Glucose Transporter Type 2/metabolism , Intestinal Absorption , Microtubules/metabolism , Phloretin/pharmacokinetics , Phlorhizin/pharmacokinetics , Protein Kinase C/antagonists & inhibitors , Rats , Signal Transduction , Tetradecanoylphorbol Acetate/pharmacokinetics , Tubulin Modulators/pharmacokinetics
6.
J Biomed Sci ; 15(4): 499-507, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18283562

ABSTRACT

Phorbol myristate acetate (PMA) causes acute lung injury (ALI). The present study was designed to elucidate the role of nitric oxide (NO), inducible NO synthase (iNOS), neutrophil elastase (NE) and other mediators in the ALI caused by PMA. In isolated rat's lungs, PMA at various doses (1, 2 and 4 mug/g lung weight) was added into the lung perfusate. Vehicle group received dimethyl sulfoxide (the solvent for PMA) 100 mug/g. We measured the lung weight changes, pulmonary arterial pressure, capillary filtration coefficient, exhaled NO, protein concentration in bronchoalveolar lavage (PCBAL) and Evan blue dye leakage. Nitrate/nitrite, methyl guanidine, proinflammatory cytokines, NE and myeloperoxidase (MPO) in lung perfusate were determined. Histopathological examination was performed. We detected the iNOS mRNA expression in lung tissue. PMA caused dose-dependent increases in variables for lung changes, and nitrate/nitrite, methyl guanidine, proinflammatory cytokines, NE and MPO in lung perfusate. The pathology was characterized by alveolar hemorrhagic edema with inflammatory cell infiltration. Scanning electron microscopy revealed endothelial damage. PMA upregulated the expression of iNOS mRNA. Our results suggest that neutrophil activation by PMA causes release of NE, upregulation of iNOS and a series of inflammatory responses leading to endothelial damage and ALI.


Subject(s)
Cytokines/physiology , Leukocyte Elastase/metabolism , Nitric Oxide Synthase Type II/genetics , Nitric Oxide/physiology , Peroxidase/physiology , Respiratory Distress Syndrome/etiology , Animals , In Vitro Techniques , Inflammation , Leukocyte Elastase/physiology , Lung , Male , Neutrophil Activation , Nitric Oxide Synthase Type II/physiology , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Respiratory Distress Syndrome/pathology , Tetradecanoylphorbol Acetate/pharmacokinetics
7.
Exp Cell Res ; 312(20): 4079-89, 2006 Dec 10.
Article in English | MEDLINE | ID: mdl-17046750

ABSTRACT

The MItf-Tfe family of basic helix-loop-helix leucine zipper (bHLH-Zip) transcription factors encodes four family members: MItf, Tfe3, TfeB and TfeC. In vitro, each protein of the family binds DNA in a homo- or heterodimeric form with other family members. Tfe3 is involved in chromosomal translocations recurrent in different tumors and it has been demonstrated, by in vivo studies, that it plays, redundantly with MItf, an important role in the process of osteoclast formation, in particular during the transition from mono-nucleated to multi-nucleated osteoclasts. Since mono-nucleated osteoclasts derive from macrophages we investigated whether Tfe3 might play a role upstream during hematopoietic differentiation. Here we show that Tfe3 is able to induce mono-macrophagic differentiation of U937 cells, in association with a decrease of cell proliferation and an increase of apoptosis. We also show that Tfe3 does not act physiologically during commitment of CD34+ hematopoietic stem cells (HSCs), since it is not able to direct HSCs toward a specific lineage as observed by clonogenic assay, but is a strong actor of terminal differentiation since it allows human primary myeloblasts' maturation toward the macrophage lineage.


Subject(s)
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/metabolism , Macrophages/metabolism , Myeloid Progenitor Cells/physiology , Antigens, Differentiation/analysis , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/genetics , Cell Cycle , Cell Differentiation , Cell Line, Tumor , Cells, Cultured , Fetal Blood/metabolism , Fetal Blood/physiology , Gene Silencing , Granulocyte Precursor Cells/metabolism , HL-60 Cells , Humans , Lipopolysaccharide Receptors/metabolism , Tetradecanoylphorbol Acetate/pharmacokinetics , Tetradecanoylphorbol Acetate/pharmacology , Transduction, Genetic
8.
Cancer Chemother Pharmacol ; 57(6): 789-95, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16231182

ABSTRACT

Phorbol esters activate protein kinase C and modulate a variety of downstream cell signaling pathways. 12-O-tetradecanoylphorbol-13-acetate (TPA) is a phorbol ester that induces differentiation or apoptosis in a variety of cell lines at low concentrations. A phase I dose escalation trial of TPA was undertaken for patients with relapsed or refractory malignancies. The starting dose was 0.063 mg/m2 and most patients were treated with an intravenous infusion of TPA on days 1-5 and 8-12 followed by a 2-week rest period prior to retreatment. Thirty-five patients were treated. A biological assay was used to monitor levels of TPA-like activity in the blood after treatment. Serious adverse events included individual episodes of gross hematuria, a grand mal seizure, syncope, and hypotension. Many patients had transient fatigue, mild dyspnea, fever, rigors, and muscular aches shortly after the infusion. Dose-limiting toxicities included syncope and hypotension at a dose of 0.188 mg/m2. Only a single patient had evidence of tumor response. These studies establish 0.125 mg/m2 as the maximally tolerated dose when TPA is administered on this schedule.


Subject(s)
Antineoplastic Agents/therapeutic use , Neoplasms/drug therapy , Tetradecanoylphorbol Acetate/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Antineoplastic Agents/blood , Antineoplastic Agents/pharmacokinetics , Female , Humans , Male , Maximum Tolerated Dose , Middle Aged , Neoplasms/metabolism , Tetradecanoylphorbol Acetate/adverse effects , Tetradecanoylphorbol Acetate/blood , Tetradecanoylphorbol Acetate/pharmacokinetics
9.
Rev. chil. tecnol. méd ; 24(2): 1141-1146, dic. 2004. graf
Article in Spanish | LILACS | ID: lil-437713

ABSTRACT

La capacidad de defensa de las células fagocíticas depende del llamado estallido respiratorio, el cual se caracteriza por una serie de reacciones generadas por la NADPH oxidasa, que lleva a la liberación de especies reactivas de oxígeno, letales para el microorganismo. El propósito de este estudio fue desarrollar un método simple para la evaluación cuantitativa del estallido respiratorio mediante Citometría de flujo para poder utilizarlo como estrategia diagnóstica en individuos con alteración inmunológicas u otras patologías clínicas. La estandarización se realizó con estudios de dosis-respuesta y tiempo-respuesta, tanto del activador forbol 12-miristato-13acetato (PMA) así como del fluorocromo 123-dihidrorodamina (DHR). Se analizaron 30 muestras de individuos normales provenientes de un banco de sangre para obtener los valores de referencia, los cuales fueron definidos como los valores de estallido respiratorio neto expresado en porcentaje de fluorescencia y que fluctuaron entre 85,3 y 95,0 con una desviación estándar de 2,4; y los expresados en intensidad media de fluorescencia (MFI), que fluctuaron entre 13,3 y 50,4 con una desviación estándar de 9,3. De esta forma, los valores se caracterizaron como aquellos iguales al promedio ± 2 desviaciones estándar, cubriéndose el 96,6 por ciento de la muestra. En conclusión, esta nueva forma de determinar el estallido respiratorio, ofrece la gran ventaja de visualizar directamente las células, dando la oportunidad de medir en forma simultánea tanto porcentaje como la intensidad media de fluorescencia celular, permitiendo obtener así resultados más exactos y precisos.


Subject(s)
Humans , Flow Cytometry , Respiratory Burst , Tetradecanoylphorbol Acetate/pharmacokinetics , Case-Control Studies , Fluorescent Dyes/pharmacokinetics , Phagocytosis , Reference Values , Rhodamines/pharmacokinetics , Time Factors
10.
J Neuroimmunol ; 149(1-2): 167-81, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15020077

ABSTRACT

The neuropeptides Vasoactive-intestinal peptide (VIP) and Pituitary adenylate-cyclase activating protein (PACAP) increased cAMP levels in three out of five human myeloid leukemic cell lines tested while an increased in calcium intracytoplasmic levels was seen only in one cell line (HEL). This increase was phospholipase C, Pertussis toxin dependent and associated with an increase in c-fos and c-jun protein expression together with the formation of functional AP-1 transcriptional factor complex. Cell exposure to VIP or PACAP resulted in a decrease in HEL cell proliferation associated with a down-regulation of the erythroid marker, Glycophorin A. Both peptides were found to increase intra-cytoplasmic calcium levels in blasts isolated from patients with myeloid leukemia. Thus VIP and PACAP are involved in the physiology and pathophysiology of human myeloid cells.


Subject(s)
Myeloid Cells/drug effects , Neuropeptides/pharmacology , Signal Transduction/drug effects , Tetradecanoylphorbol Acetate/analogs & derivatives , Vasoactive Intestinal Peptide/pharmacology , Adenosine Triphosphate/pharmacology , Bromodeoxyuridine/metabolism , Calcium/metabolism , Cell Line, Tumor , Cyclic AMP/metabolism , Cytarabine/pharmacology , Cytosol/metabolism , DNA Fragmentation/drug effects , Dose-Response Relationship, Drug , Drug Interactions , Electrophoretic Mobility Shift Assay/methods , Enzyme Inhibitors/pharmacology , Enzyme-Linked Immunosorbent Assay/methods , Estrenes/pharmacology , Flow Cytometry/methods , Glycophorins/metabolism , Humans , Immunosuppressive Agents/pharmacology , Inositol Phosphates/metabolism , Intercellular Adhesion Molecule-1/metabolism , Leukemia/pathology , Myeloid Cells/metabolism , Neuropeptides/genetics , Pituitary Adenylate Cyclase-Activating Polypeptide , Protein Binding , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Pyrrolidinones/pharmacology , RNA, Messenger/biosynthesis , Receptors, Vasoactive Intestinal Peptide/genetics , Receptors, Vasoactive Intestinal Peptide/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , Tetradecanoylphorbol Acetate/pharmacokinetics , Thrombin/pharmacology , Time Factors , Transcription Factor AP-1/metabolism , Vasoactive Intestinal Peptide/metabolism
12.
J Am Chem Soc ; 124(36): 10658-9, 2002 Sep 11.
Article in English | MEDLINE | ID: mdl-12207512

ABSTRACT

A dramatic switching of PKC agonist and antagonist activity was observed by modification of the hydrophilicity of the 12-ester side chain of phorbol. Thus, phorbol ester 4 that contains a glycol at the 12-ester chain demonstrated a pure and significant antagonist ability of PKC; however, 3 that contains an alkanol at the 12-ester chain demonstrated a potent PKC agonist activity. On the basis of the structural difference between 3 and 4 and results of the partition assay in the Hela cell/PBS buffer system, we propose that 4 acts as a translocation poison of the PKC-phorbol ester complex. The approach of controlling the agonist/antagonist activity of phorbol esters by the nature (i.e., hydrophilicity, charge, and rigidity, etc.) of the 12-ester chain may be very useful for developing selective PKC inhibitors and a potential pharmaceutical compound for anticancer therapies.


Subject(s)
Phorbol Esters/chemistry , Phorbol Esters/pharmacology , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/metabolism , Tetradecanoylphorbol Acetate/analogs & derivatives , Cell Membrane/metabolism , Enzyme Activation/drug effects , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , HeLa Cells , Humans , Phorbol Esters/pharmacokinetics , Structure-Activity Relationship , Tetradecanoylphorbol Acetate/chemistry , Tetradecanoylphorbol Acetate/pharmacokinetics , Tetradecanoylphorbol Acetate/pharmacology
13.
Oncol Res ; 13(3): 169-74, 2002.
Article in English | MEDLINE | ID: mdl-12549626

ABSTRACT

12-O-Tetradecanoylphorbol-13-acetate (TPA) is a potent stimulator of differentiation in myelocytic leukemia cells, and it has been shown to have activity in patients with acute myelocytic leukemia. Because attempts to develop a suitable mass spectrometry assay for TPA were unsuccessful (because of the lack of sufficient sensitivity), we developed a novel and highly sensitive blood level bioassay for TPA that measures ethyl acetate-extractable differentiating activity in blood. Differentiating activity in ethyl acetate extracts of blood was measured in HL-60 cells by measuring the formation of adherent cells. The sensitivity of the assay was approximately 0.1 ng TPA/ml blood. The assay for TPA has a high degree of specificity and does not measure deesterifed potential metabolites (phorbol, phorbol-13-acetate, or phorbol-12-myristate), and the presence of GM-CSF, G-CSF, interferon-alpha, or interferon-gamma does not interfere with the assay. Blood levels of TPA as measured by the bioassay immediately after an IV infusion of TPA (0.125 mg/m2; approximately 0.25 mg per patient) and 1 and 3 h later were 1.75 +/- 0.55, 0.93 +/- 0.54, and 0.69 +/- 0.42 ng/ml, respectively (mean +/- SD from eight infusions in five patients). Terminal half-lives were determined in a few patients where TPA blood levels were measured at multiple time intervals after the TPA infusion. In these patients, the terminal half-life was 11.1 +/- 3.9 h (from five infusions in four patients). To the best of our knowledge, this is the first analytical method for the measurement of TPA.


Subject(s)
Biological Assay/methods , Tetradecanoylphorbol Acetate/blood , Tetradecanoylphorbol Acetate/pharmacokinetics , Cell Adhesion/drug effects , Drug Stability , HL-60 Cells/drug effects , Half-Life , Humans , Infusions, Intravenous , Leukemia, Myeloid, Acute/drug therapy , Sensitivity and Specificity , Tetradecanoylphorbol Acetate/administration & dosage
14.
Cell Biol Int ; 25(11): 1139-48, 2001.
Article in English | MEDLINE | ID: mdl-11913958

ABSTRACT

The stimulated secretion of prostatic acid phosphatase (PAcP) has been known to be a hallmark of androgen action on human prostate epithelial cells for the last five decades. The molecular mechanism of androgen action on PAcP secretion, however, has remained mostly unknown. We investigated the molecular mechanism that promotes PAcP secretion in LNCaP human prostate carcinoma cells which express PAcP and are androgen-responsive. Treatment with 12-o-tetradecanoyl phorbol-13-acetate (TPA), a protein kinase C (PKC) activator, resulted in an increased secretion of PAcP in a dose- and time-dependent fashion. 4Alpha-phorbol, a biologically inactive isomer of TPA, had no effect. This TPA stimulation of PAcP secretion was observed 2 h after exposure, while TPA did not have a significant effect on the mRNA level even with a 6 h treatment. A23187 calcium ionophore, known to mobilize cellular calcium which is a co-factor of PKC, also activated PAcP secretion. This TPA stimulation of PAcP secretion was more potent than the conventional stimulating agent 5alpha-dihydrotestosterone (DHT) at the same concentration of 50 nM. Furthermore, the action of TPA and DHT on PAcP secretion was blocked by five different PKC inhibitors. Results also showed that DHT, as well as TPA, could rapidly modulate PKC activity. Therefore, PKC can regulate PAcP secretion, and may also be involved in DHT action on PAcP secretion.


Subject(s)
Prostatic Neoplasms/metabolism , Protein Kinase C/metabolism , Protein Tyrosine Phosphatases/metabolism , Acid Phosphatase , Dihydrotestosterone/pharmacology , Humans , Male , Signal Transduction/drug effects , Signal Transduction/physiology , Tetradecanoylphorbol Acetate/metabolism , Tetradecanoylphorbol Acetate/pharmacokinetics , Tumor Cells, Cultured
15.
Gen Pharmacol ; 34(6): 401-8, 2000 Jun.
Article in English | MEDLINE | ID: mdl-11483289

ABSTRACT

Nitrated tyrosine, implicated in protein dysfunction, is increased in various tissues in association with diverse pathological processes. Angiotensin converting enzyme (ACE) is a luminal vascular endothelial enzyme whose dysfunction is an early sign of endothelial injury. ACE contains a tyrosine critical for its enzymatic activity. Others have shown that nitrite exacerbates the ACE dysfunction of cultured endothelial cells in contact with activated polymorphonuclear neutrophils (PMN). We hypothesized that exogenous nitrite would enhance endothelial ACE dysfunction associated with PMN activation in the isolated lung. Rats received lipopolysaccharide (LPS) 2 h prior to isolated lung perfusion with Ficoll containing buffer. Either formyl-Met-Leu-Phe (fMLP, 10(-7) M) or phorbol myristate acetate (PMA, 10(-7) M) was used to activate PMN in lungs treated or not treated with 300-microM nitrite. A first pass indicator dilution method and first order reaction kinetics were used to determine ACE activity, while lung Ficoll content served as an index of vascular permeability. Both fMLP and PMA decreased endothelial ACE activity and increased pulmonary artery pressure, edema and vascular permeability. Exogenous nitrate did not potentiate the decrease in ACE activity, the lung injury or nitrotyrosine immunoreactivity of lung homogenates. In contrast to observations in cultured endothelial cells, our findings in the whole lung are compatible with the speculation of others that the rat lung has an unidentified factor, which minimizes accumulation of nitrated proteins.


Subject(s)
Endothelium, Vascular/physiology , Lung/blood supply , Nitrites/pharmacology , Tyrosine/analogs & derivatives , Animals , Blood Pressure/drug effects , Capillary Permeability/drug effects , Carcinogens/pharmacokinetics , Dimethyl Sulfoxide/pharmacokinetics , Endothelium, Vascular/enzymology , Endothelium, Vascular/injuries , Free Radical Scavengers/pharmacokinetics , Lipopolysaccharides/pharmacology , Lung/chemistry , Lung/enzymology , Male , Models, Animal , N-Formylmethionine Leucyl-Phenylalanine/adverse effects , Neutrophils/drug effects , Neutrophils/metabolism , Peptidyl-Dipeptidase A/metabolism , Rats , Rats, Wistar , Respiratory Distress Syndrome/chemically induced , Tetradecanoylphorbol Acetate/pharmacokinetics , Tyrosine/drug effects , Tyrosine/immunology
16.
Eur J Pharmacol ; 381(1): 77-84, 1999 Sep 17.
Article in English | MEDLINE | ID: mdl-10528137

ABSTRACT

The present study used structurally distinct phorbol esters to investigate the relationship between their pharmacokinetics of binding to protein kinase C (PKC) in rat brain cortex synaptosomes, their affinity for PKC in synaptosomes and ability to enhance noradrenaline release from rat brain cortex. Affinity binding studies using [3deoxyphorbol 13-tetradecanoate (dPT)=PDB&z. Gt;12-deoxyphorbol 13-acetate (dPA)=phorbol 12,13-diacetate (PDA). In intact synaptosomes PDB, dPA and PDA rapidly displaced bound [3H]PDB whereas PMA and dPT were comparatively slow. However, the displacement rates for all the phorbol esters were equally rapid in synaptosomal membranes or synaptosomes permeabilised with Staphylococcus alpha-toxin. These results suggest that the lipophilic phorbol esters (dPT and PMA) are slower to displace [3H]PDB binding because they are hindered by the plasma membrane. In brain cortex slices it was found that the rate of displacement of [3H]PDB binding was closely correlated with the degree of elevation of transmitter noradrenaline release. Thus kinetic characteristics may determine biological responses and this may be particularly evident in events which occur rapidly or where there is fast counter-regulation.


Subject(s)
Phorbol Esters/metabolism , Synaptosomes/metabolism , Animals , Binding Sites , Binding, Competitive/drug effects , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Kinetics , Male , Norepinephrine/metabolism , Phorbol 12,13-Dibutyrate/metabolism , Phorbol 12,13-Dibutyrate/pharmacokinetics , Phorbol 12,13-Dibutyrate/pharmacology , Phorbol Esters/pharmacokinetics , Phorbol Esters/pharmacology , Protein Binding , Protein Kinase C/metabolism , Rats , Rats, Sprague-Dawley , Synaptic Membranes/metabolism , Synaptosomes/enzymology , Tetradecanoylphorbol Acetate/metabolism , Tetradecanoylphorbol Acetate/pharmacokinetics , Tetradecanoylphorbol Acetate/pharmacology , Time Factors , Tritium
18.
Cancer Lett ; 98(2): 241-51, 1996 Jan 02.
Article in English | MEDLINE | ID: mdl-8556715

ABSTRACT

The non-12-O-tetadecanoylphorbol-13-acetate (TPA)-type tumor promoters, okadaic acid (OA) and calyculin-A (CAL-A), which neither interact with the phorbol ester receptor nor directly activate protein kinase C, mimic the stimulatory effects of and thapsigargin on hydroperoxide (HPx) production in mouse epidermis in vivo. The time course and dose dependency for the stimulation of HPx production by O and TPA are similar. HPx production is maximally stimulated 16 h after two applications of 2 nmol of OA at a 48-h interval. However CAL-A is a stimulator of HPx production about 4 times more potent than OA or TPA. Combinations of TPA and OA or CAL-A have subadditive effects on HPx production. The discrepancies between the abilities of various serine/threonine protein phosphatase (PP) inhibitors to stimulate HPx production suggest that PP inhibition alone is not sufficient for this response. Cycloheximide, Ca2+ antagonists, oxypurinol, diphenyliodonium, nordihydroguaiaretic acid, bromophenacyl bromide, antiinflammatory agents, and antihistamines block or decrease OA-stimulated HPx production. Although most of these inhibitors may have more than one action, their effects suggest that protein synthesis, Ca2+, xanthine oxidase and NADPH oxidase activities, the lipoxygenase pathway of arachidonic acid metabolism, and vascular permeability may be involved in the inflammatory and HPx responses that occur after tumor promoter treatment. The increased HPx-producing activity of the epidermis, therefore, may be a common event resulting from the inflammatory and tumor-promoting actions of diverse TPA- and non-TPA-type agents.


Subject(s)
Carcinogens/pharmacology , Enzyme Inhibitors/pharmacology , Ethers, Cyclic/pharmacology , Hydrogen Peroxide/metabolism , Oxazoles/pharmacology , Phosphoprotein Phosphatases/antagonists & inhibitors , Skin/drug effects , Skin/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Animals , Carcinogens/pharmacokinetics , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacokinetics , Ethers, Cyclic/pharmacokinetics , Female , Marine Toxins , Mice , Mice, Inbred Strains , Okadaic Acid , Oxazoles/pharmacokinetics , Stimulation, Chemical , Tetradecanoylphorbol Acetate/pharmacokinetics
19.
Dig Dis Sci ; 40(10): 2268-79, 1995 Oct.
Article in English | MEDLINE | ID: mdl-7587800

ABSTRACT

The initiating mechanisms involved in colonic injury are currently unknown. The goal of the current study was to examine the role of the inflammatory mediators reactive oxygen metabolites and proteases in an ex vivo model of selective epithelial permeability. Rats were prepared with exteriorized colonic chambers to which the protein kinase C (PKC) activator phorbol myristate acetate (PMA) was added in doses ranging from 5 to 800 micrograms. PMA caused a dose-dependent transient increase in epithelial permeability, but had no significant effect on microvascular permeability. There was no accumulation of neutrophils and no apparent histological changes. PMA acts via a PKC-dependent mechanism, as assessed using the PKC-inactive phorbol analog 4 alpha-phorbol didecanoate, and the response is tachyphylactic. The mechanism is independent of reactive oxygen metabolites and proteases, as shown by the lack of effect of the free radical scavengers superoxide dismutase and catalase and the general serine protease inhibitor soybean trypsin inhibitor. The classic inflammatory process does not appear to be involved in the PMA-induced epithelial permeability changes. This finding suggests that noninflammatory mechanisms may regulate the increased epithelial permeability induced by PMA. Further study to elucidate these mechanisms is of importance for understanding both normal gastrointestinal physiology and initiation of pathology.


Subject(s)
Cell Membrane Permeability/drug effects , Colon/drug effects , Protein Kinase C/agonists , Reactive Oxygen Species/metabolism , Serine Endopeptidases/drug effects , Tetradecanoylphorbol Acetate/pharmacology , Acute Disease , Animals , Colitis/chemically induced , Colitis/metabolism , Colitis/pathology , Colon/metabolism , Colon/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Epithelium/drug effects , Epithelium/metabolism , Inflammation Mediators/metabolism , Male , Rats , Rats, Sprague-Dawley , Serine Endopeptidases/metabolism , Tetradecanoylphorbol Acetate/pharmacokinetics
20.
Biol Pharm Bull ; 17(8): 1114-7, 1994 Aug.
Article in English | MEDLINE | ID: mdl-7820119

ABSTRACT

12-O-Tetradecanoylphorbol-13-acetate (TPA) binds specifically to histone H1 prepared from HeLa cells and to calf histone H1 with dissociation constants of 4.3 x 10(-7) and 9.3 x 10(-7) M, respectively. The TPA-binding to histone H1 was confirmed immunologically using a monoclonal antibody directed against an evolutionally conserved epitope of histone H1. This binding would influence DNA structure and the basal level of transcription, and may, in turn, account for the cell growth-regulatory activity of TPA.


Subject(s)
Histones/metabolism , Tetradecanoylphorbol Acetate/pharmacokinetics , Amino Acid Sequence , Animals , Antibodies, Monoclonal/immunology , Blotting, Western , Cattle , Electrophoresis, Polyacrylamide Gel , HeLa Cells , Humans , Molecular Sequence Data , Precipitin Tests , Protein Binding
SELECTION OF CITATIONS
SEARCH DETAIL